GlaxoSmithKline Pharmaceuticals today reported 6.53 per cent increase in standalone net profit at Rs 102.85 crore for the quarter ended March 31, 2015.
The company had posted net profit of Rs 96.54 crore for the January-March quarter of the previous fiscal, GSK Pharma said in a filing to the BSE.
Net sales increased marginally by 2.27 per cent to Rs 613.47 crore for the quarter of 2014-15 fiscal, compared with Rs 599.85 crore in the year-ago period, it added.
The company attributed lower sales growth to “supply constraints”.
For the quarter, GSK Pharma also reported exceptional loss of Rs 5.81 crore.
In November 2014, the company, which used to follow the January-December period as financial year, changed to the April-March period.
In a separate filing, GSK Pharma said its board of directors has recommended a dividend of Rs 62.50 per equity share for the 15-month period ended March 31, 2015.
The company’s prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases.
Shares of GSK Pharma closed at Rs 3,276.05 apiece, up 1.22 per cent from previous close on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.